"rationale","label","instanceType","id","uuid:ID","name","description"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign","StudyDesign_1","95a9c137-e4f9-4e08-aef9-0c6bf55213ba","Study Design 1","The main design for the study"
